Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05223803 · ClinicalTrials.gov registry record · Phase 2
TERPS Trial for de Novo Oligometastic Prostate Cancer
A Phase 2 study of Prostate Cancer and Oligometastatic Disease, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
- 9
- Study locations
NCT05223803 is a Phase 2 study of Prostate Cancer and Oligometastatic Disease that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 122 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower). The trial reports 9 study locations across 4 states.
The verdict
NCT05223803, a Phase 2 study of Prostate Cancer and Oligometastatic Disease, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
- 9
- Study locations
Study Summary
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Conditions Studied
Interventions
- RADIATION Prostate radiation (XRT)
- DRUG Systemic Therapy
- RADIATION Stereotactic ablative radiation therapy (SABR)
Study Locations (9)
Maryland
- Maryland Proton Treatment Center - Baltimore
- UMMC - Baltimore
- Upper Chesapeake Health - Bel Air
- Central Maryland Radiation Oncology - Columbia
- Baltimore Washington Medical Center - Glen Burnie
Pennsylvania
- Sidney Kimmel Cancer Center at Jefferson Health - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
California
- UC San Diego Moores Cancer Center - La Jolla
Virginia
- Bon Secours Cancer Institute at St. Francis - Midlothian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2022-10-18 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05223803
The ClinicalTrials.gov registry entry for NCT05223803 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (80% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Prostate radiation (XRT) is the first listed.
NCT05223803 reports 9 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT05223803 about?
NCT05223803 is a clinical study titled "TERPS Trial for de Novo Oligometastic Prostate Cancer". This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
What is the current status of trial NCT05223803?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2022-10-18. Estimated completion is 2027-07-31.
What conditions does trial NCT05223803 study?
This clinical trial studies the following conditions: Prostate Cancer, Oligometastatic Disease.
What interventions are being tested in trial NCT05223803?
The interventions under investigation include: Prostate radiation (XRT) (RADIATION), Systemic Therapy (DRUG), Stereotactic ablative radiation therapy (SABR) (RADIATION).
Who is sponsoring clinical trial NCT05223803?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05223803 being conducted?
This trial has 9 study locations across California, Maryland, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.